Every Form 4 that Petmed Express Inc (PETS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PETS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PETS filings page.
Campbell Leslie C.G. reported acquisition or exercise transactions in this Form 4 filing.
PETMED EXPRESS INC reported that Interim CEO and President Leslie C.G. Campbell received a grant of 60,000 shares of Common Stock as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan on 2026-08-11. The award vests in full on the first anniversary of the grant date, subject to continued employment and possible accelerated vesting upon death, disability, a change of control, or certain terminations of employment. Following this grant, Campbell directly holds 145,000 shares of Common Stock. An additional 30,000 shares are held in the Leslie C.G. Campbell 2020 Irrevocable Trust for family members; Campbell is not a beneficiary and disclaims beneficial ownership of those trust shares.
LaCamp James reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express IncJames LaCamp55,555 sharesAugust 11, 202790,421 shares
Batushansky Peter reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express Inc. director Peter Batushansky reported a grant of 55,555 shares of common stock as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan. The award vests in full on August 11, 2027, subject to his continued service on the Board of Directors, bringing his direct holdings to 91,928 shares.
Mennen Justin L. reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express Inc. director Justin L. Mennen received a grant of 55,555 shares of Common Stock as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan. These shares vest in full on August 11, 2027, subject to his continued service on the Board of Directors.
After this award, Mennen directly holds 98,274 shares of PetMed Express common stock.
KRULIK DOUGLAS reported acquisition or exercise transactions in this Form 4 filing.
PETMED EXPRESS INC reported equity awards to CAO and Interim CFO Douglas Krulik effective June 26, 2026. He received 32,500 restricted common shares that vest 50% on June 26, 2027 and 50% on June 26, 2028, plus 32,500 performance share units tied to total shareholder return from April 1, 2026 to March 31, 2028.
The amended insider report corrects the PSUs’ performance period description and aligns their March 31, 2028 expiration date; it states no other changes. Following the restricted stock grant, Krulik directly holds 102,500 common shares.
KRULIK DOUGLAS reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express granted CAO and interim CFO Douglas Krulik 32,500 shares of restricted common stock and 32,500 performance share units as equity compensation. The restricted shares vest 50% on June 26, 2027 and 50% on June 26, 2028, while the performance units payout depends on three-year relative total shareholder return through December 31, 2028.
Nina Capital Holdings Inc., together with related ten percent owners of PETMED EXPRESS INC, reported an open-market purchase of 25,000 shares of Common Stock at a weighted average price of $1.749 per share, in multiple trades between $1.72 and $1.75.
Following this transaction, their reported direct holdings total 2,600,000 shares, including 1,875,000 shares held by Nina Capital Holdings and 725,000 shares held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.
PetMed Express director Gian Fulgoni reported an automatic forfeiture of 26,057 shares of common stock on January 21, 2026. The Form 4 shows this as a disposition at a price of $0.00 per share, reflecting that the shares were forfeited rather than sold for cash.
According to the footnote, the forfeiture was required under the applicable award agreement for restricted shares that had been granted on October 30, 2025, and occurred due to the termination of his director service as of January 21, 2026. After this change, Fulgoni directly beneficially owns 132,299 shares of PetMed Express common stock.
PetMed Express (PETS) reported that its CAO and Interim CFO acquired 20,000 shares of restricted stock on October 30, 2025 at $0, as disclosed on a Form 4.
The award vests as to 50% of the granted shares on October 30, 2026 and 50% on October 30, 2027, subject to continued employment through each vesting date. Following this grant, the officer beneficially owns 70,000 shares.
PetMed Express (PETS) reported a director’s acquisition of 34,866 shares of restricted common stock on 10/30/2025 at $0, as disclosed in a Form 4. Following the award, the director beneficially owns 34,866 shares, held directly. The grant was made under the company’s 2024 Omnibus Incentive Plan and is scheduled to vest in two tranches: 1,020 shares on 10/19/2026 and 33,846 shares on 10/30/2026, each vesting subject to continued service on the Board of Directors.
PetMed Express (PETS) reported a director equity grant. The reporting person acquired 33,846 shares of common stock as a restricted stock award at $0 on October 30, 2025, issued under the company’s 2024 Omnibus Incentive Plan. The award vests as to all granted shares on October 30, 2026, subject to continued service on the Board of Directors. After this transaction, the reporting person beneficially owned 42,719 shares, held directly.
PetMed Express (PETS) director Leah A. Solivan reported an award of 33,846 shares of common stock on 10/30/2025 at $0 (Form 4, code A), granted as restricted stock under the company’s 2024 Omnibus Incentive Plan.
The award vests on October 30, 2026, subject to continued service on the Board of Directors. Following this grant, Solivan’s beneficial ownership is 42,289 shares, held directly.
PetMed Express (PETS) reported a director equity grant on a Form 4. On 10/30/2025, the director acquired 33,846 shares of common stock as a restricted stock award at a reported price of $0, under the company’s 2024 Omnibus Incentive Plan. Following the grant, the director beneficially owned 36,373 shares, held directly.
The award vests in full on October 30, 2026, subject to continued service on the Board of Directors.